Improving Cancer Diagnosis

Radiologist refines detection of prostate cancer

Author | Allison Wilson

Top photo: Davenport, pictured at far left, and his colleagues. Photo by Scott C. Sodenberg, Michigan Photography

Matthew S. Davenport, M.D. (Residency 2010), assistant professor of radiology and of urology, is one of the leaders of a new effort to improve cancer diagnosis at U-M and throughout Michigan.

Historically, prostate-specific antigen, or PSA, and digital rectal examination, or DRE, have been the primary methods of detecting prostate cancer at a curable stage, but these methods are not ideal. Patients with clinically significant cancers can be missed, and patients with clinically insignificant cancers can be over-treated. Davenport and his collaborators in nuclear medicine, pathology and urology have been researching innovations in MRI, PET and ultrasound-MR fusion techniques to refine prostate cancer diagnosis for several years. And it has recently become available clinically at the U-M Comprehensive Cancer Center.

"In the past, if a patient's PSA was elevated, or they had an abnormal DRE, they would get a template biopsy directed to regions of the prostate rather than a defined target," Davenport says. "MRI allows more precise detection, targeted biopsies, and the ability to better predict whether the cancer is low-risk or aggressive."

U-M was the first in the region to offer this technique and the service is expanding rapidly. Prostate cancer care providers across the state are motivated to incorporate this technology into their own programs, thanks to its promising outcomes. Davenport and his urology colleagues are partnering with radiologists and urologists at other sites, and working with the Michigan Urological Surgery Improvement Collaborative to educate providers about advanced imaging, correct reporting of prostate MRI examinations and imaging-related data collection.

Davenport is also internationally recognized for his research on the safety and efficacy of radiographic contrast media that improve the visibility of pathology on CT and MRI examinations. He has co-authored national policy statements regarding contrast media, is director of body MRI at U-M and chair of the Michigan Radiology Quality Collaborative.

More Articles About: Radiology Prostate Cancer U-M Comprehensive Cancer Center Urology
Featured News & Stories older person pouring pills into hand close up
Health Lab
Early findings suggest this cancer drug may be effective against advanced tumors caused by genetic mutations
Sparrow Health System, part of University of Michigan Health, experts release findings in a study of a cancer drug for patients with genetic mutations.
woman outside by water and woman with care team infusion
Health Lab
Immunotherapy saves woman with stage 4 colon cancer
A Michigan Medicine expert describes immunotherapy as “the future of cancer treatment” for those who qualify.
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
Could Prostate Cancer Drugs Help Fight COVID Infections?
Researchers look into a drug called proxalutamide as a potential therapeutic for the coronavirus.
man at table writing down in living room
Health Lab
Free online tool helps prostate cancer patients save on out-of-pocket drug costs
A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a Michigan Medicine study finds.
pill attacking coronavirus
Health Lab
Prostate cancer drug shows promise against COVID
Michigan Medicine researchers looked into a drug in development to treat prostate cancer called proxalutamide, which works by blocking an enzyme called TMPRSS2 (transmembrane protease, serine 2) that is regulated by androgen receptors, as a potential therapeutic for COVID.
pink purple microscopic cells
Health Lab
Study shows new approach to target deadly form of prostate cancer
A study from the University of Michigan Rogel Cancer Center uncovers a new mechanism to explain why some prostate tumors switch from a common, treatable form to a more rare and aggressive form of prostate cancer.